Agenus presents new botensilimab/balstilimab data in gastric cancer at aacr io annual meeting

Lexington, mass.--(business wire)--agenus inc. (nasdaq: agen), a leader in immuno-oncology, today presented data at the american association for cancer research (aacr) io annual meeting in los angeles, california. the oral presentation highlights translational data from the ongoing phase 2 study evaluating botensilimab (bot, multifunctional fc-enhanced anti-ctla-4) and balstilimab (bal, anti-pd-1) in combination with mink therapeutics' agent-797, an allogeneic invariant natural killer t (inkt).
AGEN Ratings Summary
AGEN Quant Ranking